These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Scotiabank lowered the firm’s price target on Geron (GERN) to $4 from $6 and keeps an Outperform rating on the shares. While the company’s Q4 ...

Geron Corp (GERN) reports a robust cash reserve and key FDA approval for Rytelo, but faces flat revenue trends and leadership changes in its commercial strategy.

Geron (NASDAQ: GERN) stock is getting crushed in Wednesday's trading. Geron stock is seeing huge sell-offs on the heels of ...

Geron shares fell 30% to $1.66 after the company reported a fourth-quarter loss that was wider than expected.

Hello and welcome to the Geron fourth quarter and full year 2024 earnings call. All lines have been placed on mute to prevent any background noise. Aft ...

Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new ...

Geron ended 2024 with a strong cash position and reported that revenues for the third and fourth quarters exceeded expectations. The company’s net product revenue for RYTELO reached $47.5 million in ...

Geron (NASDAQ:GERN) stock plunged 30% after management reportedly indicated on the company's Q4 earnings call that sales of ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to p ...

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.